Stay updated on Abemaciclib + Nivolumab in Recurrent Head & Neck Clinical Trial

Sign up to get notified when there's something new on the Abemaciclib + Nivolumab in Recurrent Head & Neck Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Abemaciclib + Nivolumab in Recurrent Head & Neck Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Removed the sponsor/institution entry (Alvin J. Siteman Cancer Center at Barnes‑Jewish Hospital and Washington University School of Medicine) and the 'Helpful Links Provided by' section from the Study Details page.
    Difference
    0.2%
    Check dated 2025-10-27T19:06:45.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    - Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T05:35:02.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Updated page version to v3.1.0 and removed a specific resource entry for Head and neck squamous cell carcinoma.
    Difference
    0.5%
    Check dated 2025-09-29T03:06:45.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.0.2 (replacing v3.0.1); the 'Back to Top' element has been removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:13:32.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-07T15:39:12.000Z thumbnail image
  8. Check
    61 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, as well as new resources related to head and neck squamous cell carcinoma and various proteins and antibodies. Notably, the previous location details have been removed.
    Difference
    4%
    Check dated 2025-08-31T11:57:39.000Z thumbnail image

Stay in the know with updates to Abemaciclib + Nivolumab in Recurrent Head & Neck Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Abemaciclib + Nivolumab in Recurrent Head & Neck Clinical Trial page.